Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper
(212) 838-1444
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact

SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=A6C1ADC7C5182DA0
http://www2.marketwire.com/mw/emailprcntct?id=2680952DAB30926D
http://www2.marketwire.com/mw/emailprcntct?id=68071DB41F5658EE

Dr. Pingpank treated the largest number of patients in Delcath's Phase III Trial while at the National Cancer Institute (NCI). This ongoing study was recently expanded to include ten leading cancer centers throughout the United States. The Phase III trial of 92 patients is comparing Progression Free Survival (PFS) in patients treated with the Delcath PHP System to a control arm receiving Best Available Care (BAC). Following completion of the Phase I trial in 2003, the FDA granted Fast Track review status and advanced the Phase I trial directly to the Phase III trial. The trial, which is governed by a Special Protocol Assessment (SPA) with the FDA, seeks to demonstrate responses in PHP patients of at least 7.8 months, versus an expected response of four months or less in patients receiving BAC.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

This release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the current belief of management. These statements relate to, among other things, the results to date of our phase III clinical trials as described above. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that any results of any trials to date are interim and may not be borne out or supported by subsequent or final results or that any such trials may not be fully completed as necessary; risks relating to our ability to further advance the development of the our system in clinical trials; risks of any failure to comply with regulations relating to our system, including FDA requirements; risks of failure to obtain the financial resources to complete development of our system; the risk that the FDA may interpret the results of our studies differently from any interpretation we may have; the risk that Dr. Pingpank's discussion as described above or elsewhere does not necessarily represent the position of or any information on behalf of Delcath, since he is not an employee, consultant or agent of or otherwise authorized to speak on behalf of Delcath, and all of the other risks discussed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper
Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact

SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=212D87D392A18D73
http://www2.marketwire.com/mw/emailprcntct?id=E8FA9CD29CC4ED19
http://www2.marketwire.com/mw/emailprcntct?id=378A0FD30C3275E4
http://www2.marketwire.com/mw/emailprcntct?id=91BD3372E6597E64

Those parties interested in participating in the live call may join by dialing (304) 345-7506 in the U.S. and referencing conference identification number 279838. A telephone replay will be available at 7:30 pm EDT the day of the live call and can be accessed by dialing (402)970-2661 in the U.S and referencing conference identification number 100539. The replay will be available until Wednesday, September 24, 2008 until 7:30 pm EDT.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact

SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=57F68137D094131C
http://www2.marketwire.com/mw/emailprcntct?id=E7777631D91F919E
http://www2.marketwire.com/mw/emailprcntct?id=5EFD1C47A00E9CFB
http://www2.marketwire.com/mw/emailprcntct?id=D94FC5DA4B4CF04B

"Dr. Nutting's presentation marks an expansion in awareness for the Delcath PHP System," stated Richard L. Taney, President and CEO of Delcath. "This is the first major presentation regarding the Phase III trial by an Investigator outside of the National Cancer Institute. As the oncology community becomes more familiar with the potential benefits of Delcath's PHP technology, this presentation will further the awareness of the Interventional Radiology Community which will be a key driver in the adoption of this unique treatment for inoperable cancers."

WAIS is a regional society of leading physicians from the western states and Canada dedicated to vascular and interventional radiology, and image-guided techniques for the diagnosis and treatment of cancer and other illnesses. Information on this organization and conference can be found at www.westernangio.org.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
Email Contact

Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper/Cass Almendral
(212) 838-1444
Email Contact
Email Contact

Public Relations Contact:
Rubenstein Associates, Inc.
Robin Wagge
(212) 843-8006
Email Contact

SOURCE: Delcath Systems, Inc.

http://www2.marketwire.com/mw/emailprcntct?id=37A3E7D4D650407C
http://www2.marketwire.com/mw/emailprcntct?id=48CCFBA4EA343527
http://www2.marketwire.com/mw/emailprcntct?id=258B6A608761474C
http://www2.marketwire.com/mw/emailprcntct?id=D825E133C9D3CC94